Another trial of Medtronic's Symplicity renal denervation device in treating hypertension shows no benefit compared with a sham procedure.
A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.
Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:
Medtronic's failed Symplicity HTN-3 renal denervation study doesn't look any better with 12 months of follow-up, according to new results presented at this year's European Society of Cardiology Congress.
Renal denervation technologies took another blow this week as 1-year results from Medtronic's (NYSE:MDT) much-lamented Symplicity HTN-3 trial still turned out no signs that the treatment is effective against hypertension.
The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.
Kona Medical announces the launch of a clinical trial for its non-invasive Surround Sound renal denervation device for treating hypertension.
Kona Medical said this week that it's launched a clinical trial of the non-invasive renal denervation device for treating hypertension it calls Surround Sound.
Researchers develop a "surveillance system" to monitor patients' electronic health records for signs of undiagnosed hypertension.
MASSDEVICE ON CALL — A computer algorithm may be able to help physicians monitor patients for signs of hypertension, a disease known as "the silent killer."
Researchers at Northwestern Medicine developed a trio of algorithms to review patients' electronic health records and alert healthcare providers that a patient may have or may be developing hypertension.
Twitter-savvy physicians and researchers mull over the latest clinical results for Medtronic's renal denervation technology, calling for more common sense and less hype in treating hypertension.